<DOC>
	<DOCNO>NCT00511875</DOCNO>
	<brief_summary>This 24 month randomize research study evaluate whether doxycycline 1 ) slow deterioration improve retinal function and/or 2 ) induce regression , slow progression , diabetic retinopathy participant 18 year age type 1 type 2 diabetes severe non-proliferative early proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Evaluation Doxycyline Verses Placebo Treatment Severe Nonproliferative Mild Moderate Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>The objective proof-of-concept study investigate whether doxycycline 1 ) slow deterioration improve retinal function and/or 2 ) induce regression , slow progression , diabetic retinopathy . The test perform Ophthalmology Departments Penn State College Medicine Glostrup Hospital , Copenhagen , Denmark . The 24 month proof-of-concept clinical study involve prospective , randomize , double-masked clinical trial include 60 adult patient type 1 type 2 diabetes severe non-proliferative diabetic retinopathy ( ETDRS level 53E ) mild moderate proliferative diabetic retinopathy ( retinal /or optic disk neovascularization less `` high-risk '' ETDRS level 61 65 ) , neovascularization disc neovascularization elsewhere &gt; 1/2 disc area panretinal photocoagulation imminently require ophthalmologist 's judgment . Systemic Exclusion Criteria : - unstable medical status ( e.g . glycemic control , blood pressure , cardiovascular disease ) opinion investigator - significant renal disease ( define serum creatinine &gt; 2.5 mg/dL ) , - systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 110 mm Hg - history headache associate tetracycline therapy - history pseudotumor cerebri - pregnancy ; woman child-bearing potential , serum pregnancy test perform . - lactate intend become pregnant study period ( least 24 month ) - sexually active woman child-bearing potential actively practice birth control use medically accept device therapy ( , intrauterine device , hormonal contraceptive , barrier device ) study period ( least 24 month ) ; since doxycycline may interfere effectiveness hormonal contraceptive , sexually active woman child-bearing potential use hormonal contraceptive require use second form contraception safeguard contraceptive failure participate study - know allergy/intolerance doxycycline ingredient study drug placebo ( e.g . cellulose , hypromellose , iron oxide , methacrylic acid copolymer , polyethylene glycol , polysorbate 80 , sugar sphere , talc , titanium dioxide , triethyl citrate ) - patient take phenytoin , barbiturates carbamazepine , gastroparesis , history gastrectomy , gastric bypass surgery otherwise deem achlorhydric BMI &gt; 30 kg/m2 also exclude altered doxycycline pharmacokinetics and/or bioavailability - patient take strontium , acitretin tretinoin exclude due potential serious drug interaction doxycycline - patient abnormal ALT AST baseline refer primary care physician medical clearance participation study</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>age ≥ 18 year old diagnosis type 1 type 2 diabetes mellitus hemoglobin A1c le 11 % prequalification visit able willing give inform consent bestcorrected ETDRS visual acuity study eye ≥ 49 letter ( 20/100 ) severe nonproliferative diabetic retinopathy ( ETDRS level 53E ) retinal and/or optic disk neovascularization less `` highrisk '' characteristic define Diabetic Retinopathy Study ( ETDRS level61 65 ) , panretinal photocoagulation imminently require ophthalmologist 's judgment able perform reliable visual field dark adaptation test central subfield thickness OCT ≤ 275microns foveal fixation present eye ( assessed fundus photography use internal fixation pointer assess investigator ) medium clarity pupil dilation sufficient highquality fundus photograph fluorescein angiograms highrisk neovascularization study eye prior panretinal photocoagulation study eye focal/grid laser photocoagulation macula within past 15 week study eye intraocular pressure &gt; 22mmHg Goldmann Tonometry study eye history par plana vitrectomy study eye vitreous preretinal hemorrhage study eye systemic intravitreal antiVEGF agent study eye fellow eye within past 3 month peribulbar steroid injection study eye fellow eye within past 6 month intravitreal triamcinolone acetonide study eye within past 4 month expectation investigator retinal photocoagulation treatment diabetic retinopathy ( e.g . focal/grid laser study eye , intravitreal triamcinolone acetonide study eye , intravitreal antiVEGF agent study fellow eye , ruboxistaurin systemic antiVEGF agent diabetic macular edema ) administer subsequent 24 month ocular condition ( diabetes ) present study eye , opinion investigator , might alter visual acuity course study ( e.g . retinal vein occlusion , uveitis ocular inflammatory disease , neovascular glaucoma , IrvineGass Syndrome , etc ) anticipate need cataract surgery study eye subsequent 24 month opinion investigator history major ocular surgery ( include cataract surgery , scleral buckle , intraocular surgery , etc ) study eye within prior 6 month anticipate within subsequent 24 month follow randomization aphakia study eye history YAG capsulotomy perform study eye within 2 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>diabetes</keyword>
	<keyword>diabetic eye study</keyword>
	<keyword>neovascularization</keyword>
</DOC>